Cytokinetics (CYTK) Assets Average (2011 - 2026)
Cytokinetics (CYTK) posted quarterly Assets Average of $1.3 billion for Q1 2026, up 1.21% year-over-year from $1.3 billion in Q1 2025, and down 5.7% quarter-over-quarter from $1.4 billion in Q4 2025.
Cytokinetics (CYTK) Assets Average (2011 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Assets Average for 15 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 1.21% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 1.21% YoY), while the FY2025 annual figure was $1.4 billion, up 26.96% from the prior year.
- Assets Average slipped to $1.3 billion in Q1 2026 per CYTK's latest filing, from $1.4 billion in the prior quarter.
- Across five years, Assets Average topped out at $1.5 billion in Q3 2024 and bottomed at $760.3 million in Q3 2023.
- Historically, Assets Average has averaged $1.1 billion across 5 years, with a median of $1.0 billion in 2022.
- Annual changes were most pronounced in 2023 — Assets Average retreated 25.15% — and 2024, when it soared 94.66%.
- Cytokinetics' Assets Average stood at $1.0 billion in 2022, then declined by 25.15% to $782.5 million in 2023, then jumped by 81.33% to $1.4 billion in 2024, then rose by 0.82% to $1.4 billion in 2025, then fell by 5.7% to $1.3 billion in 2026.
- Business Quant data shows CYTK's Assets Average at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 1.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Bn |
| Mar 31, 2026 | 1.35 Bn |
| Dec 31, 2025 | 1.43 Bn |
| Sep 30, 2025 | 1.33 Bn |
| Jun 30, 2025 | 1.24 Bn |
| Mar 31, 2025 | 1.33 Bn |
| Dec 31, 2024 | 1.42 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.17 Bn |
| Mar 31, 2024 | 816.20 Mn |
| Dec 31, 2023 | 782.47 Mn |
| Sep 30, 2023 | 760.26 Mn |
| Jun 30, 2023 | 834.86 Mn |
| Mar 31, 2023 | 952.30 Mn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 923.84 Mn |
| Jun 30, 2022 | 813.99 Mn |
| Mar 31, 2022 | 848.79 Mn |
| Dec 31, 2021 | 834.43 Mn |
| Sep 30, 2021 | 695.92 Mn |